Sixty-fifth Legislative Assembly of North Dakota

FIRST ENGROSSMENT with Senate Amendments ENGROSSED HOUSE BILL NO. 1120

Introduced by

Human Services Committee

(At the request of the Department of Human Services)

- 1 A BILL for an Act to amend and reenact subsection 3 of section 50-24.6-04 of the North Dakota
- 2 Century Code, relating to the prior authorization program.

3 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:

4 SECTION 1. AMENDMENT. Subsection 3 of section 50-24.6-04 of the North Dakota

5 Century Code is amended and reenacted as follows:

| 6 | 3. | <u>a.</u> | Exc | eptFor individuals twenty-one years of age and older, except for quantity |
|----|----|---------------|-------------|--|
| 7 | | | limit | ts that may be no less than the pharmaceutical manufacturer's package |
| 8 | | | inse | ert, or brand name drugs with a generic equivalent drug for which the cost to |
| 9 | | | the | state postrebate is less than the brand name drugs, in the aggregate, <u>or</u> |
| 10 | | | gen | eric drugs with a brand name equivalent drug for which the cost to the state |
| 11 | | | pos | trebate is less than the generic drug, the department may not prior authorize |
| 12 | | | the | following medication classes: |
| 13 | | a. | (1) | Antipsychotics; |
| 14 | | b. | <u>(2)</u> | Antidepressants; |
| 15 | | C. | <u>(3)</u> | Anticonvulsants; |
| 16 | | d. | <u>(4)</u> | Antiretrovirals, for the treatment of human immunodeficiency virus; and |
| 17 | | e. | <u>(5)</u> | Antineoplastic agents, for the treatment of cancer ; and |
| 18 | | f. | Stin | nulant medication used for the treatment of attention deficit disorder and |
| 19 | | | atte | ntion deficit hyperactivity disorder. |
| 20 | | <u>b.</u> | For | individuals under twenty-one years of age, except for quantity limits that may |
| 21 | | | <u>be r</u> | no less than the pharmaceutical manufacturer's package insert, brand name |
| 22 | | | <u>drug</u> | gs with a generic equivalent drug for which the cost to the state postrebate is |
| 23 | | | less | than the brand name drugs, in the aggregate, or generic drugs with a brand |
| 24 | | | nam | ne equivalent drug for which the cost to the state postrebate is less than the |
| | | | | |

17.8071.03000

Sixty-fifth Legislative Assembly

| 1 | | generic drug, the department may not prior authorize the following medication | | |
|----|-----------|---|--|--|
| 2 | | <u>classes:</u> | | |
| 3 | | (1) Antipsychotics; | | |
| 4 | | (2) Antidepressants: | | |
| 5 | | (3) Anticonvulsants; | | |
| 6 | | (4) Antiretrovirals, for the treatment of human immunodeficiency virus; | | |
| 7 | | (5) Antineoplastic agents, for the treatment of cancer; and | | |
| 8 | | (6) Stimulant medication used for the treatment of attention deficit hyperactivity | | |
| 9 | | disorder. | | |
| 10 | <u>C.</u> | The restrictions of subdivision b do not apply for individuals under twenty-one | | |
| 11 | | years of age, who have five or more concurrent prescriptions for psychotropic | | |
| 12 | | medications. | | |
| 13 | <u>d.</u> | Prior authorization for individuals under twenty-one years of age is required for | | |
| 14 | | five or more concurrent prescriptions for antipsychotics, antidepressants, | | |
| 15 | | anticonvulsants, benzodiazepines, mood stabilizers, sedative, hypnotics, or | | |
| 16 | | medications used for the treatment of attention deficit hyperactivity disorder. The | | |
| 17 | | department shall grant authorization to exceed the limits after a prescriber | | |
| 18 | | requesting authorization consults with a board certified pediatric psychiatrist | | |
| 19 | | approved by the department. | | |